Latest News at the Center
national cancer institute: Human Papillomavirus | Did You Know?
Did you know that infection with about a dozen HPV types is associated with cancer among both men and women? Watch the HPV Did You Know? Watch this video to learn about the types of cancers caused by HPV, incidence rates in the U.S., HPV vaccination, and screening.For more statistics on HPV, click here. Help raise awareness about HPV!.
Medical News Today Quotes The Center for Cell Reprogramming in Recent Article
Medical News Today has recently highlighted the Center for Cell Reprogramming and Drs. Richard Schlegel and Xuefeng Liu in their recent article, "HPV and Cancer: Key Mechanism May Suggest Treatment."
CRC Technology in Review: Dependency of a Therapy Resistant State of Cancer Cells on a Lipid Peroxidase Pathway
Nature Journal has recently pubslished a paper which highlights Conditional Reprogramming technology as a milestone of patient-derived models and the important potential of discovery of targets and precision oncology.
Schlegel Strives to Create Another Cervical Cancer Game Changer
Dr. Richard Schlegel, co-inventor of the Georgetown-owned technology which led to the world-wide known HPV vaccine, seeks to find a medical adavance for women currently infected with HPV and a precancerous condition which can lead to the development of cervical cancer.
By Decoding How HPV Causes Cancer, Researchers Find A New Potential Treatment Strategy
ThisA study that teases apart the biological mechanisms by which human papillomaviruses (HPV) cause cancer has found what researchers at Georgetown Univerisyt Medical Center say is a new strategy that might provide targeted treatment for these cancers...
Conditional Reprogramming: An Interview with Dr. Richard Schlegel on Growing Cancer Cells
This February The National Cancer Institute (NCI) interviewed Dr. Richard Schlegel for the Cancer Currents: An NCI Cancer Research Blog. Dr. Schlegel discusses conditional reprogramming and growing cancer cells, ongoing progress and its future in studies.
Center for Cell Reprogramming Inventors Recognized at the 2017 Patent Awards Ceremony
Congratulations to honorees Drs. Richard Schlegel and Xuefeng Liu on their recognition as inventors at the Georgetown University 2017 Patent Awards Ceremony! Drs. Schlegel and Liu are recognized for their patent, "Immortalization of Epithelial Cells and Methods of Use."
Conditionally Reprogrammed Cells Mentioned in European Urology Journal
European Urology has recently released an article title, "Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer," which features CRC technology within prostate cancer.
Anton Wellstein: Embracing Uncharted Territory
The Center for Cell Reprogramming's Deputy Director, Dr. Anton Wellstein, discusses why he encourages students to study cancer research and how the Center's goals and purpose behind conditionally reporgrammed cells is providing more opportunities for developing targeted therapies. Featured in Georgetown's University Medical Center News, Dr. Wellstein shares his role within the Center and future possibilities.
NCI Cancer Close Up 2016
This year the National Cancer Institute reached out to their designated cancer centers to select images for their 2016 NCI Cancer Close Up project. This project featured several images at the molecular and cellular level. Further promoting their project, more images were collected and placed in their special online collection. Members of Dr. Richard Schlegel's laboratory, including Seema Agarwal, PhD, and Ewa Krawczyk, PhD, submitted several photos which were then chosen and placed in their online collection.
Georgetown Researchers Describe Method to Study Real Time Cancer Invasion
Dr. Anton Wellstein is co-senior investigator of a study at Georgetown Lombardi Comprehensive Cancer Center in which a team is studying the steps that allow cancer investigators to track cancer cell invations and metastasis in transparent zebrafish embryos...in real time. Their hopes are that answers will be found to cancer questions in a shorter amount of time and advance the understanding of cancer biology and experimental drug testing.
Podcast: Radiolab Featuring Cell Immortalization
NPR's Radiolab recently featured a story on cell immortalization titled "Life's Limit." The hour-long podcast discusses the theory of cells dividing reapeatidly and the scientific research behind the discovery of their limits.
Cambridge Healthtech Institute's 8th International Leaders in Biobanking Congress
The Center for Cell Reprogramming's Deputy Director, Anton Wellstein, MD, will be delivering a talk this September at Cambridge Healthtech Institute's 8th International Leaders in Biobanking Congress. This year the focus will be on Applying Biospecimen Science to Advance Biomedical Research. Dr. Wellstein will deliver a talk on Circulating Nucleic Acids in Cancer Treatment Monitoring.
National Press Foundation Visits the Center for Cell Reprogramming
Members of the National Press Foundation gathered this past January to Georgetown University Medical Center and the Center for Cell Reprogramming. While here they visited the CCR labs and experienced a personal tour from Director, Dr. Richard Schlegel.
National Academy of Inventors: Clinical Translation of HPV and Cell Culture Research Presentation
April 28, 2015
Dr. Richard Schlegel was invited to present at the 2015 National Academy of Inventors' Annual Conference earlier this year. Dr. Schlegel spoke about the clinical translations of HPV and cell culture research.
Precision Medicine for Cancer with Next-Generation Functional Diagnostics
November 5, 2015
Conditionally Reprogrammed Cells (CRC) was recently cited in Nature Reviews Cancer Journal as one of the next-generation approaches for cancer precision medicine being considered.
Dr. Richard Schlegel Highlighted in Northwestern's Medical Scientist Training Newsletter
The Fall 2015 Medical Scientist Training Program Newsletter at Northwestern University's Feinberg School of Medicine features alumnus Dr. Richard Schlegel. The spotlight features a background on the work of Dr. Schlegel as well as some questions on his training and time at Northwestern University.
August 21, 2015
President Barack Obama announced his 2016 Budget to include a $215 million investment in Precision Medicine Initiative which will extend $70 million for NCI. In moving forward with the increase in funding and support from the President, NCI discusses the focus to promote precision medicine, which includes the use of Dr. Richard Schlegel's CRC technology. The method will be used to establish a repository of laboratory models collected from patient tumor samples that will aid researchers towards a more in-depth drug resistance investigation. To see a detailed look of the CRC method and its involvement in the initiative please see the following presentations:
Continuing Research with CRCs and HPV Education
July 9, 2015
Dr. Richard Schlegel's continual effort on conditionally reprogrammed cells (CRCs) has helped Dr. Sherrie Wallington, of Georgetown's Lombardi Comprehensive Cancer Center, with her endeavors of educating the Washington D.C. community on the effects of HPV and the benefits of its vaccine.
Georgetown Honors Innovation at Patent Award Ceremony
February 20, 2015
Georgetown's Office of Technology Commercialization recently celebrated oustanding faculty accomplishments in technology transfer and communications. Among those recognized was Dr. Richard Schlegel and startup company Propagenix for their research collaborations on cell immortalization technology. To learn more about Propagenix, click here.
GUMC Researchers Honored
January 13, 2015
Georgetown University's student newspaper, The Hoya, has been serving students since 1920. This January they feature Dr. Richard Schlegel for his recent recognition as a 2014 Fellows of the National Academy of Inventors (NAI) for the discovery of the HPV vaccine.
A Bed of Mouse Cells Helps Human Cells Thrive In the Lab
January 7, 2015
Dr. Richard Schlegel speaks with Richard Harris, NPR, to talk about using his groundbreaking techniques in cell reprogramming to test artemisinin-a drug commonly used to treat malaria-to kill cervical cancer cells.
Medical Center Researchers Named National Academy of Inventors Fellows
December 16, 2014
Dr. Richard Schlegel has been named one of the 2014 Fellows of the National Academy of Inventors (NAI) for his groundbreaking discovery of the HPV vaccine. Read how the technology he co-developed has helped drop HPV infections by 56 percent in the US, according to the American Cancer Society.
Researchers Test Cancer Treatments on Patients’ Own Cells
November 13, 2014
Dr. Richard Schlegel is quoted in The Boston Globe's news story which highlights research recently published by Dr. Jeff Engelman, Director of Thoracic Oncology at Massachusetts General Hospital. Dr. Engelman co-led a group of physicians and researchers towards new steps in personalized cancer treament using technology invented by Dr. Schlegel.
Center for Cell Reprogramming: Redefining Personalized Medicine
The Center for Cell Reprogramming continues to grow as it is featured in the latest edition of the Georgetown University Medical Center Magazine. Here, the Center is discussed as a new global research hub within the Georgetown community and how the developing "Georgetown Method" is redefining personalized and regenerative medicine.
Research & Innovation at Georgetown University Medical Center
August 14, 2014
Dr. Richard Schlegel was recently featured in Georgetown University Medical Center's video about groundbreaking research and how it is affecting lives within and outside the GUMC community.
New Tool to Grow Cancer Cells Streamlines Laboratory Research
May 15, 2014
With the use of conditionally reprogrammed cells growing in research labs at Georgetown University Medical Center, Dr. Anna Reigel explains how the cells are helping her research improve and provide reliable results.
GUMC: As Medicine Gets More Precise, Complexities Mount
December 6, 2013
At the Doctors Speak Out luncheon, Dr. Richard Schlegel is among a panel of experts speaking on the future of precision medicine. Here, Dr. Schlegel discusses the analysis behind the "Georgetown Method."
Georgetown Awards HPV Vaccine and Mathematics Researchers
October 16, 2013
Dr. Richard Schlegel receives the President's Award for Distinguished Scholar - Teacher during the Fall Faculty Convocation for helping create a vaccine for human papillomavirus (HPV).
Center to Drive Georgetown Discoveries in Cellular Reprogramming
March 27, 2013
Georgetown University Medical Center introduces the Center for Cell Reprogramming to the university and community, with Dr. Richard Schlegel as Director of the Center. Collaborations are underway as research with conditionally reprogrammed cells (CRCs) are being used for biology-based studies and phase I clinical trials within the MedStar Georgetown Cancer Network.
Georgetown Doc Works Toward Personalized Cancer Care
October 12, 2012
Dr. Richard Schlegel speaks with WAMU 88.5 Metro Connection's Jonathan Wilson to talk about what the latest medical trial has revealed with conditionally reprogrammed cells.
Keeping Cells Alive in the Lab
January 19, 2012
Leading a team of Georgetown researchers, Dr. Richard Schlegel has a technique which will keep cells alive indeifinitely and redifine personalized cancer medicine. Here, he explains the process and potential the research has towards regenerative medicine as well as decoding the molecular differences between a patient's normal and tumor cells.
Lab Technique Immortalizes Cells
December 29, 2011
Researchers at Georgetown University Medical Center work to create a lab technique that could accelerate biomedical research and personalized medicine.
Breakthrough May Help Oncologists Find Individual Therapies
December 19, 2011
Discovering a way to keep individual cancer patient's normal and tumor cells alive in a laboratory is just the beginning as Georgetown and National Institutes of Health researchers work to take on personalized cancer medicine.
John Carroll Awards 2011
April 30, 2011
Dr. Richard Schlegel is honored with The Patrick Healy Award presented by the Alumni Association at Georgetown University for his research, which led to the first cancer vaccine, and his future efforts in cell immortalization.
Georgetown Celebrates Patents for Cancer Prevention, Other Inventions
February 8, 2011
Dr. Richard Schlegel is among 29 Georgetown inventors recognized during the university’s first Patent Award Ceremony for his accomplishments with the HPV vaccine.
Remarks from the Oscar B. Hunter Jr. Chair Inauguration
December 14, 2009
Remarks by Georgetown University President, Dr. John J. DeGioia, towards the contributions made by Dr. Richard Schlegel and his appointment as the inaugural holder of the Oscar Benwood Hunter Chair in Pathology at the Georgetown University Medical Center.
Georgetown University: Witness to History
January 23, 2009
Dr. Richard Schlegel discusses the story behind discovering the first vaccine for cervical cancer and describes his work with the Bill and Melinda Gates Foundation, along with his laboratory and the National Institutes of Health (NIH), to develop second and third generation vaccines.
Findings Raise New Questions About HPV
May 10, 2007
NPR speaks with Dr. Richard Schlegel and a cancer survivor about the possible future of HPV vaccines. Listen to their discussion about the link with HPV and some throat cancers and how this could be paving a way for mandatory vaccines that protect against the virus which is already a major cause of cervical cancer.
GUMC Research Leads to First Cancer Vaccine
Dr. Richard Schlegel and his team of Georgetown University researchers reach a major medical milestone following the Food and Drug Administration's approval for the first cancer vaccine.
GUMC Research Leads to Cancer Vaccine
June 8, 2006
After more than 20 years of research on the human papillomavirus, Dr. Richard Schlegel and a collaborative team of researchers at Georgetown have led to the development of the HPV vaccine - a medical breakthrough which will prevent HPV infections and prohibit cases of cervical cancer.